Tango Therapeutics (TNGX)
(Delayed Data from NSDQ)
$6.90 USD
-0.30 (-4.17%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $6.90 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Tango Therapeutics, Inc. [TNGX]
Reports for Purchase
Showing records 21 - 40 ( 43 total )
Company: Tango Therapeutics, Inc.
Industry: Unclassified
USP1 in Focus; Remain Excited on Prospects for TNG348
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Q1 Financials; First TNG908 Clinical Data - All Signals in The Right Direction
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Q4 Financials; Almost Time to Tango with TNG908 Data
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Financial Results Reported; Increasing PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Several Preclinical Posters Presented Recently; 3Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Q3 Financials; ENA and SITC Presentations Highlight Robust Programs
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Biotechnology- EORTC-NCI-AACR 2022: Covered Companies Roundup
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Pursuing Synthetic Lethality With TANDEM; Initiating at Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Reports of the Death of Synthetic Lethality are Grossly Exaggerated
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Q2 Financials; Execution Ongoing Across Multiple Programs
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Q4 Financials; TNG908 Ph 1/2 Study Kicks Off; Positive Preclinical Updates
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Q3 Financials; IND filing and initial TNG908 data in 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Abstracts and Sessions Relevant to Covered Companies at AACR-NCI-EORTC
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R